E
Epitopea
Biotech & Life Sciences · Montreal, Canada · Founded 2021
Transatlantic cancer immunotherapeutics company MoreLess
Epitopea is a transatlantic cancer immunotherapeutics company with operations in Cambridge, UK, and Montreal, Canada, established in 2021. The company is focused on developing immunotherapies to treat cancer by targeting a novel class of tumor-specific antigens (TSAs) known as Cryptigen™ antigens.
These antigens are broadly shared among patients with the same type of cancer. Epitopea leverages a proprietary platform to identify these markers on the surface of cancer cells. The company is developing a pipeline of accessible, off-the-shelf RNA-based immunotherapies. This approach aims to provide broadly applicable cancer treatments.
Epitopea has entered into a license and research collaboration agreement with MSD (Merck) to identify Cryptigen™ tumor-specific antigens. The company has secured over $45 million in financing to support the strategic development and clinical entry of its lead product candidate, Cryptigen™.
Keywords: cancer immunotherapeutics, RNA-based immunotherapies, tumor-specific antigens, Cryptigen, oncology, biotechnology, clinical development, off-the-shelf therapies, transatlantic, cancer treatment
Company overview
Epitopea company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Montreal, Canada
- Employees
- 50
- Open positions
- None listed
- Dealroom signal
- 87.8
Valuation & funding
Epitopea funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2024 | $31M | $124M | Cambridge Innovation Capital · Invest Quebec · Fonds de solidarité FTQ · Jonathan Milner | ↗ |
| GRANT✓Other financing | Sep 2024 | $658K | — | Undisclosed | ↗ |
| GRANT✓Other financing | Aug 2024 | $662K | — | UK Research and Innovation | — |
| SEED✓Equity / VC | Apr 2022 | $14M | $54M | Advent Life Sciences · Fonds de solidarité FTQ · Harrington Discovery Institute · Cambridge Innovation Capital | ↗ |
| SPINOUT✓Other financing | Apr 2021 | $0 | — | University of Montreal | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Epitopea website traffic
Latest recorded traffic for Epitopea is 3.2K monthly website visits, up 68.4% over the last three months. Epitopea's team grew 8.7% over the past year.
Comparisons
Epitopea compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Epitopea's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Epitopea's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Epitopea has talent and traffic
team presence
In the news
Latest news about Epitopea
Recent press, funding announcements, and product moves mentioning Epitopea — open to read from the original sources.
Market sentiment
What the market is saying about Epitopea
An AI-synthesized read of the highest-engagement posts about Epitopea on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epitopea’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.